NanoVibronix

Focus: NanoVibronix is an Israeli biotech company specializing in therapeutic ultrasound devices across multiple indications including urinary tract infections, wound healing, and pain management. The company operates as a small, focused device-biotech hybrid with a diversified pipeline spanning Phase 2 through Phase 4 programs.

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About NanoVibronix

AI assessmentNot Hiring

No open roles listed right now. Follow NanoVibronix to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

7 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

UroShield

Baacterial Colonization

N/A

Clinical Trials (1)

NCT03090373The Effect of Surface Acoustic Waves on the Prevention of Colonization in Longterm Indwelling Urinary Caatheters

N/A

Help build intelligence for NanoVibronix

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Exposure to emerging therapeutic ultrasound technology platform with 7 active pipeline programs across multiple therapeutic areas
Early-stage company (founded 2015) offers potential equity upside and meaningful individual impact on device development strategy
Diversified pipeline reduces single-program risk, with programs ranging from Phase 2 (NG Shield, UroShield) to Phase 4 (PainShield)

Watch Out For

Zero current job openings signal potential hiring freeze or organizational constraint limiting growth opportunities
Lack of publicly available financial data, funding information, and revenue metrics raises transparency concerns about company health and sustainability
Small, Israel-based organization may limit access to US pharma network effects and regulatory expertise at scale

Generated by Claude from NanoVibronix's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Active UroShield

Quality of Life

N/A

Clinical Trials (1)

NCT06319352Evaluation of Quality-of-Life Improvements Using UroShield Device

N/A

PainShield SAW Patch Device

Trigeminal Neuralgia

N/A

Clinical Trials (1)

NCT02801630An Evaluation of the Effect of a Surface Acoustic Wave Patch Device on the Symptons of Trigeminal Neuralgia

N/A

Evaluation of Surface Acoustics Ultrasound Device for the Treatment of Patients With Percutaneous Ne

Urinary Tract Infection

N/A

Clinical Trials (1)

NCT00702286Evaluation of Surface Acoustics Ultrasound Device for the Treatment of Patients With Percutaneous Nephrostomy Catheters

N/A

NG Shield

Intubation, Nasogastric

Phase 2

Clinical Trials (1)

NCT00781248Safety and Efficacy Study of the NG Shield, a Device Intended to Reduce Pain and Discomfort Level Related to Nasogasstric Tube Usage

Phase 2

UroSshield

Urinary Tract Infection

Phase 2/3

Clinical Trials (1)

NCT00446732The Use of the UroShield Device in Patients With Indwelling Urinary Catheters

Phase 2/3

PainShield

Wounds

Phase 4

Clinical Trials (1)

NCT00737425Safety and Efficacy Study of Pain Shield Device to Treat Subjects Following Laparoscopic-Assisted Abdominal Surgery

Phase 4

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Founded: 2015

Portfolio: 7 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo